Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
暂无分享,去创建一个
Neil Vargesson | W. Figg | E. Gardner | N. Vargesson | William D Figg | Lynda Erskine | Christina Therapontos | Erin R Gardner | C. Therapontos | L. Erskine
[1] M. Joseph. THALIDOMIDE AND CONGENITAL ABNORMALITIES , 1962, Developmental medicine and child neurology.
[2] M. Gütschow,et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. , 2003, Cancer research.
[3] R. Nicosia,et al. The thin prep rat aortic ring assay: A modified method for the characterization of angiogenesis in whole mounts , 2004, Angiogenesis.
[4] Viktor Hamburger,et al. A series of normal stages in the development of the chick embryo , 1992, Journal of morphology.
[5] C. Harris,et al. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. , 2004, Antioxidants & redox signaling.
[6] L. Schuler‐Faccini,et al. New cases of thalidomide embryopathy in Brazil. , 2007, Birth defects research. Part A, Clinical and molecular teratology.
[7] M. Gütschow,et al. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. , 2004, Journal of medicinal chemistry.
[8] B. Jennett,et al. HEAD INJURY AND ADMISSION POLICY , 1979, The Lancet.
[9] R W Smithells,et al. Recognition of thalidomide defects. , 1992, Journal of medical genetics.
[10] N. Munshi,et al. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs , 2005, Leukemia.
[11] G. Macpherson,et al. Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice , 2004, Clinical Cancer Research.
[12] W. Figg,et al. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.
[13] T D Stephens,et al. Hypothesis: thalidomide embryopathy-proposed mechanism of action. , 2000, Teratology.
[14] C. Tabin. A developmental model for thalidomide defects , 1998, Nature.
[15] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[16] W. Figg,et al. Thalidomide metabolism and hydrolysis: mechanisms and implications. , 2006, Current drug metabolism.
[17] A. Jurand. Early changes in limb buds of chick embryos after thalidomide treatment. , 1966, Journal of embryology and experimental morphology.
[18] J. Shaughnessy,et al. Thalidomide induces limb deformities by perturbing the Bmp/Dkkl/Wnt signaling pathway , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] W. Lenz,et al. Foetal Malformations Due to Thalidomide , 1962 .
[20] G. Martin,et al. Genetic evidence that FGFs have an instructive role in limb proximal–distal patterning , 2008, Nature.
[21] W. Lenz. A short history of thalidomide embryopathy. , 1988, Teratology.
[22] J. Hinchliffe,et al. Birth and death of cells in limb development: A mapping study , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.
[23] B. Weinstein,et al. In vivo imaging of embryonic vascular development using transgenic zebrafish. , 2002, Developmental biology.
[24] D. Ellison. Mental deficiency no ground for divorce. , 1966, Lancet.
[25] R. T. Williams. Teratogenic effects of thalidomide and related substances. , 1963, Lancet.
[26] M. Indhumathy,et al. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells , 2006, BMC Cell Biology.
[27] E. Laufer,et al. Smad7 misexpression during embryonic angiogenesis causes vascular dilation and malformations independently of vascular smooth muscle cell function. , 2001, Developmental biology.
[28] T D Stephens,et al. Mechanism of action in thalidomide teratogenesis. , 2000, Biochemical pharmacology.
[29] S James Matthews,et al. Thalidomide: a review of approved and investigational uses. , 2003, Clinical therapeutics.
[30] R. Smithells. Defects and Disabilities of Thalidomide Children , 1973, British medical journal.
[31] L. Klotz,et al. Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. , 2008, Molecular pharmaceutics.
[32] Y. Hashimoto,et al. Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. , 2007, Chemical & pharmaceutical bulletin.
[33] P. Dennis,et al. Importance of the Stress Kinase p38α in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells , 2006, Clinical Cancer Research.
[34] Y. Hashimoto,et al. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. , 2006, Chemical & pharmaceutical bulletin.
[35] A. Wilkie. Why study human limb malformations? , 2003, Journal of anatomy.